Common use of Additional Information and Where to Find It Clause in Contracts

Additional Information and Where to Find It. In connection with the proposed merger between Novartis and Chinook, Novartis and Chinook intend to file relevant materials with the SEC, including a preliminary and definitive proxy statement to be filed by Chinook. The definitive proxy statement and proxy card will be delivered to the stockholders of Chinook in advance of the special meeting relating to the proposed merger. CHINOOK’S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF NOVARTIS AND CHINOOK WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about Novartis and Chinook, once such documents are filed with the SEC, through the website maintained by the SEC at xxx.xxx.xxx. Novartis and Chinook make available free of charge at the Novartis website and Chinook’s website, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.

Additional Information and Where to Find It. In The Company intends to file with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement and furnish or file other materials with the SEC in connection with the proposed merger between Novartis and Chinooktransaction. Once the SEC completes its review of the preliminary proxy statement, Novartis and Chinook intend to file relevant materials with the SEC, including a preliminary and definitive proxy statement to will be filed by Chinook. The definitive proxy statement with the SEC and proxy card will be delivered mailed to the stockholders of Chinook the Company. This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that the Company may file with the SEC in advance of the special meeting relating to connection with the proposed mergertransaction. CHINOOKBEFORE MAKING ANY VOTING DECISION, XXXXXXXXXX’S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND THOSE OTHER MATERIALS CAREFULLY AND IN ITS THEIR ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF NOVARTIS AND CHINOOK WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors The proxy statement and other relevant materials (when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC’s website at xxx.xxx.xxx. In addition, security holders will be able to obtain a free copy copies of the proxy statement and such other documents containing important information about Novartis and Chinook, once such documents are filed with from AdTheorent by going to the SEC, through the Company’s Investor Relations page on its corporate website maintained by the SEC at xxx.xxx.xxx. Novartis and Chinook make available free of charge at the Novartis website and Chinook’s website, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statementxxx.xxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed merger between Novartis and Chinookmerger, Novartis and Chinook intend Zoom intends to file relevant materials with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Zoom and a proxy statement of Five9 (the “proxy statement/prospectus”). After the registration statement has been declared effective by the SEC, including a preliminary and definitive the proxy statement to be filed by Chinook. The definitive proxy statement and proxy card statement/prospectus will be delivered to the stockholders of Chinook in advance of the special meeting relating to the proposed mergerFive9. CHINOOK’S STOCKHOLDERS BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SECURITY HOLDERS OF ZOOM AND FIVE9 ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND ANY SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER THAT WILL BE FILED BY EACH OF NOVARTIS AND CHINOOK WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTIONMERGER. Investors and security holders will be able to obtain a free copy copies of the proxy statement statement/prospectus (when available) and such other documents containing important information about Novartis filed by Zoom and Chinook, once such documents are filed Five9 with the SEC, without charge, through the website maintained by the SEC at xxx.xxx.xxxxxxx://xxx.xxx.xxx. Novartis and Chinook make Copies of the documents filed with the SEC by Zoom will be available free of charge at under the Novartis website and Chinook’s website, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC. The contents SEC Filings heading of the websites referenced above are not deemed to Investor Relations section of Zoom’s website at xxxxx://xxxxxxxxx.Xxxx.xx/. Copies of the documents filed with the SEC by Five9 will be incorporated by reference into available free of charge under the proxy statement.Financials & Filings heading of the Investor Relations section of Five9’s website at xxxxx://xxxxxxxxx.Xxxx0.xxx/.

Additional Information and Where to Find It. This communication may be deemed to be solicitation material in respect of the proposed acquisition of Xura. In connection with the proposed merger between Novartis and Chinookmerger, Novartis and Chinook intend to file Xura will be filing relevant materials with the Securities and Exchange Commission (the “SEC”), including a preliminary and proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement to be filed by Chinook. The with the SEC, Xura will mail or otherwise make available the definitive proxy statement and a proxy card will be delivered to the stockholders of Chinook in advance of each stockholder entitled to vote at the special meeting relating to the proposed mergertransaction. CHINOOK’S XURA STOCKHOLDERS AND OTHER INVESTORS ARE URGED ADVISED TO CAREFULLY READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED BY EACH OF NOVARTIS AND CHINOOK WITH THE SEC IN CONNECTION WITH RESPECT OF THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE WHEN THEY BECOME AVAILABLE, AS THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION MERGER AND THE PARTIES TO THE PROPOSED TRANSACTIONMERGER. Investors Xura stockholders and security holders will be able to other investors may obtain a free copy copies of the definitive proxy statement, the preliminary proxy statement and such other relevant materials in connection with the proposed merger (when they become available), along with other documents containing important information about Novartis and Chinook, once such documents are filed by Xxxx with the SEC, at the SEC’s website (xxxx://xxx.xxx.xxx) or through the investor relations section of Xxxx’s website maintained by the SEC at xxx.xxx.xxx. Novartis and Chinook make available free of charge at the Novartis website and Chinook’s website, respectively (in the “Investors” sectionxxxx://xxx.xxxx.xxx), copies of materials they file with, or furnish to, the SEC. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.